Exposure to estrogens is a risk factor for human breast cancer. Experiments on estrogen metabolism, formation of DNA adducts, carcinogenicity, mutagenicity and cell transformation led to and support the hypothesis that reaction of specific estrogen metabolites, catechol estrogen-3,4-quinones, with DNA can generate the critical mutations to initiate breast, prostate and other human cancers. The major initiating pathway is illustrated in Figure 1. Estrone (E 1 ) and estradiol (E 2 ) can be metabolically converted to 4-OHE 1 (E 2 ) by cytochrome P450 (CYP)1B1. Oxidation of these catechol estrogens leads to the corresponding catechol estrogen-3,4-quinones, which can react with DNA to form very small amounts of stable adducts, which remain in DNA unless removed by repair, and predominant amounts (99%) of depurinating adducts, which detach from DNA, leaving behind apurinic sites. Errors in the repair of these sites can lead to the critical mutations that can initiate breast, prostate and other human cancers.
Cancer biomarkers
The depurinating adducts are shed from cells and tissues into the bloodstream and are excreted in urine. This allows their identification and quantification as biomarkers of risk of developing breast, prostate and other human cancers. High adduct levels have been detected in analysis of urine and serum from women that are at high risk for breast cancer or already have the disease. These analyses are conducted by using ultraperformance liquid chromatography/tandem mass spectrometry, a technology developed in our laboratory. In an initial study of such women, highly significant differences were observed when urine samples from normal-risk women were compared to high-risk women or those with breast cancer. Similar results were obtained in a second, larger study of women with and without breast cancer and at high risk for the disease. In addition, analysis of urine samples from men with and without prostate cancer showed that men with the disease have relatively high levels of estrogen-DNA adducts compared to men without prostate cancer. These results have been confirmed in a second, larger study.
